Recombinant clusterin and use thereof in the treatment and prevention of disease
View Patent ↗Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).
1. A method of treating or preventing a cardiovascular disease in a subject comprising administering an effective amount of a composition comprising a polypeptide comprising a Clusterin coding sequence, said coding sequence having at least 95% sequence identity to SEQ ID NO: 3, said sequence not including Clusterin nuclear localization signal sequence (LEEAKKK; SEQ ID NO: 27) and not including the Clusterin transmembrane domain sequence (LLLFVGLLL; SEQ ID NO: 28).
2. The method of claim 1 , wherein the Clusterin polypeptide is fused to a heterologous polypeptide sequence.
3. The method of claim 2 , wherein the heterologous polypeptide sequence comprises a protease cleavage site.
4. The method of claim 3 , wherein the protease cleavage site is a thrombin cleavage site.
5. The method of claim 1 , wherein the Clusterin coding sequence has at least 98% sequence identity to SEQ ID NO: 3.
6. The method of claim 1 , wherein the subject has heart disease.
7. The method of claim 6 , wherein the subject further has hypercholesterolemia, hypertension, hyperglycemia and/or thrombogenesis.
8. The method of claim 1 , wherein the cardiovascular disease is hypertension, hyperlipidemia, hypercholesterolemia, hyperglycemia, hypertension, atherosclerosis and atherosclerosis-associated ischemic heart failure, stenosis, calcification of cardiovascular tissues or stroke.
9. The method of claim 8 , wherein the cardiovascular disease is hyperlipidemia or hypercholesterolemia.
10. The method of claim 8 , wherein the cardiovascular disease is atherosclerosis, vascular calcification, valve tissue calcification or stenosis.
11. The method of claim 1 , wherein the cardiovascular disease is myocardial infarction and cerebral infarction.
12. The method of claim 1 , wherein the cardiovascular disease is diabetes, a diabetic vascular complication, vascular inflammation, vascular cell death or destruction of vascular wall.
13. The method of claim 1 , wherein the effective amount is an amount effective to reduce blood cholesterol, blood glucose, blood triglyceride, increase efflux of intracellular cholesterol and/or increase vascular or cardiac cell survival.
14. The method of claim 1 , wherein the composition is administered by intravenous injection, intratissue injection and/or catheter delivery.
15. The method of claim 1 , wherein the polypeptide is aglycosylated.
16. The method of claim 1 , wherein the polypeptide comprises a tag sequence.
17. The method of claim 16 , wherein the tag sequence is a polyhistidine tag.
18. The method of claim 16 , wherein the tag sequence is positioned N-terminally relative to the Clusterin coding sequence.
19. The method of claim 16 , wherein the tag sequence is positioned C-terminally relative to the Clusterin coding sequence.
20. The method of claim 16 , further comprising a protease cleavage site positioned between the tag sequence and the Clusterin coding sequence.
21. The method of claim 20 , wherein the protease cleavage site it a thrombin or enteropeptidase cleavage site.